Investors

Overview

CTI BioPharma is a biopharmaceutical company focused on the acquisition, development and commercialization of novel targeted therapies covering a spectrum of blood-related cancers that offer a unique benefit to patients and healthcare providers. CTI BioPharma has a late-stage development pipeline, including pacritinib, CTI BioPharma’s lead product candidate for the treatment of patients with myelofibrosis. CTI BioPharma is headquartered in Seattle, Washington. Our management and investor relations team provide updates throughout the year through conference calls, investor events, press releases and SEC filings. We invite you to sign up for our investor alerts and listen to our archived and live presentations.

To CTI’s knowledge, all press releases, scientific papers and abstracts, and the information contained within them were timely and accurate when issued. The continued accuracy of this material beyond the date of issuance and posting on the website is not assured. CTI has no intention of updating this information and specifically disclaims any duty to do so. These documents may contain forward-looking statements. Actual results could vary dramatically as a result of known and unknown risks and uncertainties. Please see Terms of Use for this website.

IR Contact

 
  • Current Quote
  • Stock Chart
NASDAQ:CTIC
$0.83 + 0.02 (2.47%)
Day High:$0.84
Day Low:$0.81
Volume:65,421
07/16/194:00 p.m. ET
Delayed at least 15 minutes.

Maeve Conneighton
Ph +1-212-600-1902
CTI@argotpartners.com


 

Recent News

MORE
DateTitle 
Jun 13, 2019CTI BioPharma to Present at the JMP Securities Life Sciences Conference on Thursday, Jun. 20
SEATTLE, June 13, 2019 /PRNewswire/ -- CTI BioPharma Corp. (CTI BioPharma) (NASDAQ: CTIC) today announced that management will provide a corporate overview at the JMP Securities Life Sciences Conference at 2:00 p.m. EDT in New York City. Presentation details: Event: JMP Securities Life Sciences Conference Date: Thursday, Jun. 20 Time: ... 
Printer Friendly Version
May 29, 2019CTI BioPharma to Present at the Jefferies Global Healthcare Conference on Wednesday, Jun. 5
SEATTLE, May 29, 2019 /PRNewswire/ -- CTI BioPharma Corp. (CTI BioPharma) (NASDAQ: CTIC) today announced that management will provide a corporate overview at the Jefferies Global Healthcare Conference at 4:30 p.m. EDT in New York City. Presentation details: Event: Jefferies Global Healthcare Conference Date: Wednesday, Jun. 5 Time: ... 
Printer Friendly Version
May 02, 2019CTI BioPharma Reports First Quarter 2019 Financial Results
SEATTLE, May 2, 2019 /PRNewswire/ -- CTI BioPharma Corp. (Nasdaq: CTIC) today reported its financial results for the first quarter ended March 31, 2019. "Advancing our U.S. and European development program for pacritinib for the treatment of myelofibrosis patients with severe thrombocytopenia remains our top priority for 2019, and we anticipate multiple important milestone events for pacritinib this year," said Adam R. Craig, M.D., Ph.D., President and Chief Executive Officer of CTI BioPharma. ... 
Printer Friendly Version

Events

MORE
There are currently no events scheduled.

Presentation

DateTitle
June 2019
Download Documentation CTI BioPharma Corporate Presentation
Get help downloading or viewing the above file types
Data provided by Nasdaq. Minimum 15 minutes delayed.